Orphazyme (CPSE:ORPHA) - Stock Price, News & Analysis

ORPHA Stock Overview

Orphazyme A/S does not have significant operations.

ORPHA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings have grown 29.3% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue (DKK0)

Highly volatile share price over the past 3 months

Has less than 1 year of cash runway

Does not have a meaningful market cap (DKK39M)

Orphazyme A/S Competitors

BioPorto

CPSE:BIOPOR

kr.486.0m

Longeveron

NasdaqCM:LGVN

US$5.5m

Quantum Genomics Société Anonyme

ENXTPA:ALQGC

€4.0m

iBio

NYSEAM:IBIO

US$7.0m

Price History & Performance

Summary of all time highs, changes and price drops for Orphazyme
Historical stock prices
Current Share Price	kr.1,100.00
52 Week High	kr.5,370.00
52 Week Low	kr.407.00
Beta	0.14
1 Month Change	-10.16%
3 Month Change	-19.12%
1 Year Change	41.03%
3 Year Change	-98.27%
5 Year Change	-98.08%
Change since IPO	-98.63%

Recent updates

What Type Of Shareholders Make Up Orphazyme A/S' (CPH:ORPHA) Share Registry?

Mar 04

How Many Orphazyme A/S (CPH:ORPHA) Shares Do Institutions Own?

Nov 19

Shareholder Returns

	ORPHA	DK Biotechs	DK Market
7D	0%	-1.3%	0.4%
1Y	41.0%	-14.0%	23.8%

Return vs Industry: ORPHA exceeded the Danish Biotechs industry which returned -14% over the past year.

Return vs Market: ORPHA exceeded the Danish Market which returned 23.8% over the past year.

Price Volatility

Is ORPHA's price volatile compared to industry and market?
ORPHA volatility
ORPHA Average Weekly Movement	11.6%
Biotechs Industry Average Movement	7.6%
Market Average Movement	4.5%
10% most volatile stocks in DK Market	9.5%
10% least volatile stocks in DK Market	2.9%

Stable Share Price: ORPHA's share price has been volatile over the past 3 months.

Volatility Over Time: ORPHA's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of Danish stocks.

About the Company

Founded	Employees	CEO	Website
2009	1	Jakob Bendtsen	www.orphazyme.com

Orphazyme A/S does not have significant operations. Previously, the company was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Orphazyme A/S Fundamentals Summary

How do Orphazyme's earnings and revenue compare to its market cap?
ORPHA fundamental statistics
Market cap	kr.38.84m
Earnings (TTM)	-kr.26.05m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.5x

P/E Ratio

Is ORPHA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ORPHA income statement (TTM)
Revenue	kr.0
Cost of Revenue	kr.0
Gross Profit	kr.0
Other Expenses	kr.26.05m
Earnings	-kr.26.05m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-737.65
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ORPHA perform over the long term?

See historical performance and comparison

ORPHA Stock Overview

Rewards

Risk Analysis

Orphazyme A/S Competitors

CPSE:BIOPOR

kr.486.0m

NasdaqCM:LGVN

US$5.5m

ENXTPA:ALQGC

€4.0m

NYSEAM:IBIO

US$7.0m

Price History & Performance

Recent News & Updates

No independent directors

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Orphazyme A/S Announces Board Changes

Orphazyme A/S to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Orphazyme A/S Revises Earnings Guidance for the Year 2022

Recent updates

No independent directors

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Orphazyme A/S Announces Board Changes

Orphazyme A/S to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Orphazyme A/S Revises Earnings Guidance for the Year 2022

Orphazyme American Depositary Shares - Sponsored to Be Deleted from Other OTC

Orphazyme A/S Announces Board Appointment

Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022

KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.

Orphazyme A/S Announces Executive Changes

Orphazyme A/S(CPSE:ORPHA) dropped from S&P Global BMI Index

Orphazyme A/S announced delayed amended 20-F filing

Orphazyme A/S announced delayed 20-F filing

Orphazyme A/S to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Orphazyme A/S, Annual General Meeting, May 21, 2022

Forecast to breakeven in 2024

Orphazyme A/S Announces Update on Regulatory Review of Arimoclomol in the European Union

Orphazyme A/S Elects Andrew Mercieca as Member of the Board of Directors

Orphazyme Provides Update for Planned NDA Resubmission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the United States

Orphazyme to Present Additional Data on Arimoclomol’s Mechanism of Action During 2022 Annual Worldsymposium™

Orphazyme A/S Announces CEO Changes

Orphazyme A/S Revises Earnings Guidance for the Year 2021

Forecast to breakeven in 2024

Orphazyme A/S Maintains its Outlook for the Full Year 2021

Price target decreased to kr.81.00

Orphazyme A/S Announces Publication of Results from Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C in the Journal of Inherited Metabolic Disease

Independent Director Martijn Kleijwegt has left the company

Independent Director Remi P. Droller has left the company

Independent Director Anders Hedegaard has left the company

CytRx Corporation Announces 24-Month Interim Results of an Open-Label Extension Trial of Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Consensus revenue estimates fall to kr.95.0m

Price target increased to kr.127

Orphazyme Provides Earnings Guidance for the Year of 2021

Orphazyme A/S Announces Topline Data from Pivotal Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Independent Director has left the company

What Type Of Shareholders Make Up Orphazyme A/S' (CPH:ORPHA) Share Registry?

Orphazyme A/S Appoints Christophe Bourdon as Chief Executive Officer, Effective on April 1, 2021

Price target lowered to kr.135

Orphazyme A/S to Showcase Data on Arimoclomol in Niemann-Pick Disease Type C During the 2021 Annual Worldsymposium™

New 90-day high: kr.78.30

CytRx Corporation Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C

Orphazyme A/S Announces the U.S. Food and Drug Administration Has Extended the Review Period of the New Drug Application

New 90-day low: kr.56.30

Orphazyme A/S Announces Executive Changes

Orphazyme A/S, Annual General Meeting, Mar 25, 2021

Orphazyme A/S to Report First Half, 2021 Results on Aug 24, 2021

How Many Orphazyme A/S (CPH:ORPHA) Shares Do Institutions Own?

Orphazyme A/S Submits European Marketing Authorisation Application for Arimoclomol for Treatment of Niemann-Pick Disease Type C

CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol

New 90-day low: kr.66.00

Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million.

Orphazyme A/S Provides Update on Previously Announced Global Offering

Orphazyme A/S Elects Carrolee Barlow as Board of Director

New 90-day low: kr.80.60

New 90-day low - kr.87.00

Shareholder Returns

Price Volatility

About the Company